40 Results for "

Anti-allodynic

" in MedChemExpress (MCE) Product Catalog:
Products (40)

40 Results for "Anti-allodynic" in MCE Product Catalog:

37
37 Publications Verification
Cat. No.: HY-N0304
CAS No.: 59-92-7
Synonyms: Levodopa; 3,4-Dihydroxyphenylalanine
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
37
37 Publications Verification
Cat. No.: HY-N0304A
CAS No.: 63302-01-2
Synonyms: Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18101A
CAS No.: 206996-13-6
Research Areas:  

Neurological Disease

BD-1063 dihydrochloride is a selective σ-1 receptor antagonist with inhibitory activity against TRPC5 and TRPM3. BD-1063 dihydrochloride exerts anti-hyperalgesic and anti-allodynic effects by inhibiting sustained calcium influx mediated by TRPC5 and TRPM3, and reverses the effects of Carrageenan (HY-125474). BD-1063 dihydrochloride also significantly reduces excessive ethanol self-administration behavior. BD-1063 dihydrochloride is widely used in studies on the mechanisms underlying neuropathic pain, inflammatory hyperalgesia, and alcohol abuse and dependence .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15451
CAS No.: 1048973-47-2
Purity:  99.26%
Synonyms: BZO-HEXOXIZID
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0304R
CAS No.: 59-92-7
Synonyms: Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0630
CAS No.: 64421-28-9
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13545
CAS No.: 251579-55-2
Target:  

Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0304S2
CAS No.: 586971-29-1
L-DOPA- 13C is the 13C labeled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
Cat. No.: HY-B0696A
CAS No.: 145821-59-6
Synonyms: NO050328 hydrochloride; NO328 hydrochloride; TGB hydrochloride
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
loading...
    loading...
Cat. No.: HY-N0304S
CAS No.: 713140-75-1
Synonyms: Levodopa-d6; 3,4-Dihydroxyphenylalanine-d6
L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
Cat. No.: HY-150270A
CAS No.: 1239578-80-3
Purity:  99.62%
NP-1815-PX sodium is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC50 of 0.26 μM against human P2X4 receptors. NP-1815-PX sodium specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX sodium selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX sodium not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX sodium exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX sodium is used in studies related to asthma and inflammatory bowel disease (colitis) .
loading...
    loading...
Cat. No.: HY-112692
CAS No.: 2099681-31-7
Purity:  ≥96.0%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

AT-121 is a bifunctional nociception and mu opioid receptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .
loading...
    loading...
Cat. No.: HY-110199
CAS No.: 1221349-53-6
Purity:  ≥99.0%
Target:  

TRP Channel

Research Areas:  

Neurological Disease

TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC50 values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models .
loading...
    loading...
Cat. No.: HY-123532
CAS No.: 73903-17-0
Purity:  99.95%
Synonyms: VUF6002
Target:  

Histamine Receptor

Research Areas:  

Neurological Disease

JNJ10191584 (VUF6002) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 shows 540-fold selectivity to H4 receptor over H3 receptor with a Ki value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively .
loading...
    loading...
Cat. No.: HY-W101299
CAS No.: 54831-20-8
Research Areas:  

Metabolic Disease

N-Acetyl-D-allo-isoleucine is an amino acid derivative. N-Acetyl-D-allo-isoleucine is promising for research of amino acid metabolism, such as abnormal isoleucine metabolism .
loading...
    loading...
Cat. No.: HY-N0304S1
CAS No.: 201417-12-1
Synonyms: Levodopa-13C6; 3,4-Dihydroxyphenylalanine-13C6
L-DOPA- 13C6 is the 13C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
Cat. No.: HY-145830
CAS No.: 2762422-55-7
Purity:  99.32%
Target:  

Adenylate Cyclase

Research Areas:  

Neurological Disease

AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC50 of 0.54 μM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain .
loading...
    loading...
Cat. No.: HY-N0630R
CAS No.: 64421-28-9
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .
loading...
    loading...
Cat. No.: HY-150270
CAS No.: 1239578-79-0
NP-1815-PX is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC50 of 0.26 μM against human P2X4 receptors. NP-1815-PX specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX is used in studies related to asthma and inflammatory bowel disease (colitis) .
loading...
    loading...
Cat. No.: HY-106010
CAS No.: 1050478-18-6
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

LBP1 is an orally active and low brain penetrant CB1 receptor agonist. LBP1 exhibits significant anti-allodynic and anti-hyperalgesic effects in rodent models of neuropathic pain .
loading...
    loading...